Sharifiaghdas Farzaneh, Narouie Behzad, Taheri Maryam, Jalali Saba, Shalbafan Bita, Azadvari Mohaddeseh, Dadpour Mehdi, Rouientan Hamidreza, Ahmadzade Mohadese, Hanafi Bojd Hamideh
Department of Urology, Shahid Labbafinejad Medical Center, Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Urology, Zahedan University of Medical Sciences, Zahedan, Iran.
SAGE Open Med. 2023 Jun 25;11:20503121231178047. doi: 10.1177/20503121231178047. eCollection 2023.
Most multiple sclerosis patients have urological complications such as lower urinary tract symptoms. This study was conducted to evaluate the prevalence of these symptoms and whether they result in a urological evaluation.
A cross-sectional study of 517 multiple sclerosis patients at Tehran's referral multiple sclerosis center and neurology clinics between 2018 and 2022 was performed. Data were collected through interviews after patients completed informed consent forms. Urological examinations, including urine analysis and ultrasonography, were evaluated as final assessments. The data were analyzed using descriptive and inferential statistical tests in Statistical Package for Social Science.
Among all participants, the prevalence of lower urinary tract symptoms was 73% ( = 384), with urgency (44.8% = 232) being the most common symptom. The prevalence of intermittency was significantly higher among women ( = 0.004). There was no gender-significant difference in terms of the prevalence of other symptoms ( > 0.050). Lower urinary tract symptoms were significantly correlated with age, clinical course, disease duration, and disability ( < 0.001). Additionally, 37.3% and 18.7% of patients with lower urinary tract symptoms, as well as 17.9% and 37.5% of patients with multiple sclerosis attacks, respectively, had undergone urine analysis and ultrasonography.
Multiple sclerosis patients rarely undergo urological evaluations during the course of their disease. Proper assessment is essential as these symptoms are among the most detrimental manifestations of this disease.
大多数多发性硬化症患者存在泌尿系统并发症，如下尿路症状。本研究旨在评估这些症状的患病率以及它们是否会导致泌尿系统评估。
对2018年至2022年间在德黑兰转诊的多发性硬化症中心和神经病学诊所的517例多发性硬化症患者进行了横断面研究。在患者签署知情同意书后，通过访谈收集数据。将包括尿液分析和超声检查在内的泌尿系统检查作为最终评估。使用社会科学统计软件包中的描述性和推断性统计测试对数据进行分析。
在所有参与者中，下尿路症状的患病率为73%（n = 384），其中尿急（44.8%，n = 232）是最常见的症状。间歇性症状在女性中的患病率显著更高（P = 0.004）。在其他症状的患病率方面，没有显著的性别差异（P > 0.050）。下尿路症状与年龄、临床病程、疾病持续时间和残疾程度显著相关（P < 0.001）。此外，分别有37.3%和18.7%的下尿路症状患者以及17.9%和37.5%的多发性硬化症发作患者接受了尿液分析和超声检查。
多发性硬化症患者在疾病过程中很少接受泌尿系统评估。由于这些症状是该疾病最有害的表现之一，因此进行适当的评估至关重要。
